Alitretinoin in dermatology-An update
Aditya Kumar Bubna
Indian Journal of Dermatology · 2015
doi:10.4103/0019-5154.164426 (opens in a new tab)
We email you when a new notice or a question about this paper appears.
Abstract
Alitretinoin is a pan retinoic acid agonist. It was initially used as 0.1% gel in the management of localized Kaposi′s sarcoma. At present, the use of systemic alitretinoin has proved extremely efficacious in the management of recalcitrant chronic hand eczema. Furthermore, there have been other retinoid responsive dermatosis that have demonstrated remission post usage of systemic alitretinoin. With a better toxicity profile, compared to the other systemic retinoids, alitretinoin could be considered a valuable treatment option in the near future for the treatment of these dermatologic disorders.
Abstract licence: CC BY-NC-SA
References55
40 more references, whose wording the paper’s licence keeps private.
All 55 referencesReads
Read by people on this page
None yet.
Checked or read by AI through naulon
None yet.
A person counts once a day per paper. We keep no cookie and no address: a reader is a hash that changes every day. Any month under five reads shows no number.
Are you an author?
Is this your paper?
Claim it to add your note and be paid when agents cite it. Free.